The practice of clinical pharmacists in dynamic monitoring and drug abnormal early warning was introduced, including medical order review, drug reorganization, dosage analysis and abnormal growth monitoring, interpretation and implementation of department indicators, follow-up and feedback of continuous monitoring and abnormal early warning, etc. The role of clinical pharmacists in this management was evaluated by comparing the category changes of top 20 drugs in terms of consumption sum, the changes of consumption sum of key monitored drugs, the increase changes of outpatient and emergency drug cost per time and inpatient drug cost per case from 2020 to 2022. The results showed that during 2020-2022, the composition of the top 20 drug categories in terms of consumption sum was more reasonable, and the consumption amount of key monitored drugs, the average outpatient and emergency drug costs and hospitalization drug costs showed a decreasing trend year by year. Compared with 2021, the consumption amount of key monitored drugs, outpatient and emergency drug cost per time and inpatient drug cost per case were decreased by 10.07%, 7.20% and 17.70% in 2022, respectively. It can be seen that clinical pharmacists play an important role in drug dynamic monitoring and abnormal early warning, and it is effective means to control drug cost and to promote rational drug use.

1.国家卫生健康委办公厅, 国家中医药局办公室. 关于印发第一批国家重点监控合理用药药品目录（化药及生物制品）的通知[EB/OL]. (2019-07-01) [2023-04-26].http://www.nhc.gov.cn/yzygj/s7659/201907/d356ce8a4ba1461ca66c544724dffc5e.shtml.

2.国家卫生健康委. 关于印发加强医疗机构药事管理促进合理用药的意见的通知[EB/OL]. (2020-02-26)[2023-04-26]. http://www.nhc.gov.cn/yzygj/s7659/202002/ea3b96d1ac094c47a1fc39cf00f3960e.shtml.

3.刘梅, 罗燕梅, 董志强.实行药品零差价对临床药品应用的影响[J].中国医院药学杂志, 2018, 38(24): 2603-2606. [Liu M, Luo YM, Dong ZQ. Effect of zero price difference on the application of clinical drugs[J]. Chinese Journal of Hospital Pharmacy, 2018, 38(24): 2603-2606.] DOI: 10.13286/j.cnki.chinhosppharmacyj.2018.24.22.

4.高枫, 韦波, 李永勤,等. 构建临床药品使用动态监控超常预警机制的探索[J]. 中国医院, 2007, 11(10): 4-6. [Gao F, Wei B, Li YQ, et al. Establishment of the dynamic-monitoring and early-warning mechanism of the abnormal use of clinical drugs, 2007, 11(10): 3-6.] DOI: 10.3969/j.issn.1671-0592.2007.10.002.

5.毛璐, 李锦, 甄健存.优化动态监测项目及超常预警对于医院合理用药的效果分析[J].中国医院药学杂志, 2017, 37(23): 2396-2399. [Mao L, Li J, Zhen JC. Influence of dynamic monitoring optimization and abnormal early warning on rational drug use in hospitals[J]. Chinese Journal of Hospital Pharmacy, 2017, 37(23): 2396-2399.] DOI: 10.13286/j.cnki.chinhosppharmacyj.2017.23.20.

6.国家卫生健康委医政司. 国家卫生健康委办公厅关于2021年度全国三级公立医院绩效考核国家监测分析情况的通报[EB/OL]. (2021-03-30) [2023-04-26]. http://www.nhc.gov.cn/yzygj/s3594q/202212/f40bfe4606eb4b1d8e7c82b1473df9ae.shtml.

7.国家卫生健康委办公厅. 国家卫生健康委办公厅关于2019年度全国三级公立医院绩效考核国家监测分析有关情况的通报[EB/OL]. (2021-03-30) [2023-04-26]. http://www.nhc.gov.cn/yzygj/s3594q/202103/559684cae3e6485fb309976b081ac3f0.shtml.

8.魏安华, 桂玲, 刘东. 胸部恶性肿瘤围手术期抗凝药物预防静脉血栓栓塞症的回顾性分析[J]. 药物流行病学杂志, 2021, 30(7): 473-476. [Wei AH, Gui L, Liu D. Retrospective analysis of perioperative venous thromboembolism prophylaxis in thoracic cancer patients[J]. Chinese Journal of Pharmacoepidemiology, 2021, 30(7): 473-476.] DOI: 10.19960/j.cnki.issn1005-0698.2021.07.009.

9.郑婷婷, 李锦, 卞婧,等.以合理用药绩效管理促进医院高质量发展[J].中国卫生质量管理, 2022, 29(12): 47-50. [Zheng TT, Li J, Bian J, et al. To promote the high quality development of hospitals by performance management of rational drug use[J]. Chinese Health Quality Managment, 2022, 29(12): 47-50.] DOI: 10.13912/j.cnki.chqm.2022.29.12.11.

10.李立勇.医疗机构药事管理质量影响因素分析[J].临床医药文献电子杂志, 2018, 5(72): 195-196. [Li LY. Analysis of influencing factors of pharmaceutical management quality in medical institutions[J]. Journal of Clinical Medical, 2018, 5(72): 195-196.] DOI: 10.16281/j.cnki.jocml.2018.72.172.

11.刘秀兰, 付伟, 刘东, 等. 2020年湖北省二级以上医疗机构药事管理质量控制指标实施现状调研[J]. 中国药师, 2022, 25(4): 682-687. [Liu XL, Fu W, Liu D, et al. Investigation and analysis of the implementation status of pharmaceutical administration indicators in medical institutions above the secondary level in Hubei province in 2020[J]. China Pharmacist, 2022, 25(4): 682-687.] DOI: 10.19962/j.cnki.issn1008-049X.2022.04.022.

12.宫雪. 不稳定型心绞痛患者住院总费用及药品费用影响因素[J]. 中国药物经济学, 2023, 18(3): 28-31. [Gong X. Hospitalization costs and the influencing factors of drug costs in the patients with unstable angina[J]. China Journal of Pharmaceutical Economics, 2023, 18(3): 28-31.] DOI:  10.12010/j.issn.1673-5846.2023.03.005.

13.胡承, 郭婧怡, 于祥田.多因素分析方法在控制混杂因素中的应用[J].中华糖尿病杂志, 2022, 14(1): 84-87. [Hu C, Guo JY, Yu XT. The application of multiple-factor analysis in controlling confounding factors [J]. Chinese Journal of Diabetes Mellitus, 2022, 14(1): 84-87.] DOI: 10.3760/cma.j.cn115791-20210902-00481.